







### MeRes100 - BRS Enhanced Radiopacity




MeRes100 couplets of tri-axial RO markers at either end of the scaffold, gives a sense of virtual tubing and high operator comfort.

Distance from edge of Balloon RO marker (both proximal & distal) to edge of Scaffold RO = 1.3 mm

### MeRes100 - BRS Best-in-the-Class Strut Thickness



MeRes100 is a 100 µm strut thickness scaffold with a propensity to minimize vascular injury & ensure early endothelialization.




Unique manufacturing process, novel hybrid design concept incorporating strut width variability allows for best-in-class, *DES-like strut thickness* in MeRes100.

### MeRes100 - BRS Best-in-the-Class Crossing Profile



Average profile of 1.2 mm for Ø 3.00 mm



Unique crimping process, novel hybrid design concept incorporating low strut thickness allows for best-in-class, *DES-like crossing profile* in MeRes100.

6Fr Guide Catheter for all diameters



### MeRes100 - BRS TECHNICAL SPECIFICATIONS

**SCAFFOLD BACKBONE**  
 Scaffold Material : BioResorbable PLLA (Poly L-lactide)  
 Scaffold Strut Thickness : 100 µm  
 Scaffold Diameters : 2.25, 2.50, 2.75, 3.00, 3.25, 3.50, 4.00 mm  
 Scaffold Lengths : 13, 16, 19, 24, 29, 32, 37, 40 mm

**SCAFFOLD RO MARKERS**  
 Tri-axial RO Markers : Platinum (Couplets of tri-axial RO markers at either end, 120° apart from each other)

**TOP COAT-DRUG+POLYMER**  
 Drug : Sirolimus  
 Equivalent Drug Dose : 1.25 µg / mm<sup>2</sup>  
 Polymer : BioResorbable PLLA (Poly D, L-lactide)

**DELIVERY SYSTEM**  
 Delivery System : Rapid Exchange  
 Nominal Pressure (NP) : 9 atm  
 Rated Burst Pressure (RBP) : 16 atm  
 Balloon Overhang : < 0.5 mm  
 Shaft Outer Diameter : Proximal 1.95 F / Distal 2.7 F  
 Radiopaque Markers : 2 - Platinum / Iridium  
 Usable Catheter Length : 140 cm  
 Guide Catheter Compatibility : 6 F (Min. I D 0.070" / 1.8 mm)  
 Max. Guidewire : 0.014" (0.36 mm)

### MeRes100 - BRS ORDERING INFORMATION

Dia / Lengths	13 mm	16 mm	19 mm	24 mm
2.50 mm	MRL25013	MRL25016	MRL25019	MRL25024
2.75 mm	MRL27513	MRL27516	MRL27519	MRL27524
3.00 mm	MRL30013	MRL30016	MRL30019	MRL30024
3.25 mm	MRL32513	MRL32516	MRL32519	MRL32524
3.50 mm	MRL35013	MRL35016	MRL35019	MRL35024
4.00 mm	MRL40013	MRL40016	MRL40019	MRL40024

Dia / Lengths	29 mm	32 mm	37 mm	40 mm
2.50 mm	MRL25029	MRL25032	MRL25037	MRL25040
2.75 mm	MRL27529	MRL27532	MRL27537	MRL27540
3.00 mm	MRL30029	MRL30032	MRL30037	MRL30040
3.25 mm	MRL32529	MRL32532	MRL32537	MRL32540
3.50 mm	MRL35029	MRL35032	MRL35037	MRL35040
4.00 mm	MRL40029	MRL40032	MRL40037	MRL40040

MeRes100™ is not approved and not available for sale in the United States.  
 1. OCT Image courtesy of Dr. Daniel Chamie, Dante Pazzanese Institute of Cardiology, Sao Paulo, Brazil. 2. Data on file at Meril Life Sciences Pvt. Ltd. Information for the use only in countries with applicable health authority product registrations.

Meril

More to Life

Meril Life Sciences Pvt. Ltd.  
 Survey No. 135/139,  
 Bilakhia House,  
 Muktesand Marg, Chala,  
 Vapi 396 191,  
 Gujarat, India.  
 T +91 260 305 2100  
 F +91 260 305 2125

Meril, Inc.  
 116, Village Boulevard, Suite 200,  
 Princeton, NJ 08540, USA.  
 T +1 609 951 2287  
 F +1 609 520 1702

Meril South America  
 Doc Med LTDA  
 Al. dos Tupiniquins,  
 1079 - Cep: 04077-003 - Moema,  
 Sao Paulo, Brazil.  
 T +55 11 3624 5935  
 F +55 11 3624 5936

Meril GmbH  
 Bornheimer Strasse 135-137,  
 D-53119 Bonn,  
 Germany.  
 T +49 228 7100 4000  
 F +49 228 7100 4001

Meril Tibbi Hizmetler  
 Imalat Ve Ticaret A. S.  
 Icerenkoy Mah. Cetinkaya Sok.  
 Prestij Plaza No: 28, Kat:4, Atasehir,  
 34752 Istanbul / TURKEY  
 T +90 53 2272 5172

Meril China Co., Ltd.  
 2301b 23f, Lixin Plaza,  
 no 90, South Hubin Road,  
 Xiamen, China  
 T 0086-592-5368505  
 F 0086-592-5368519

Meril SA Pty, Ltd.  
 Unit 7, Stony Ridge Office Park,  
 Corner Witkoppen Road And  
 Waterford,  
 Paulshof - Johannesburg,  
 Gauteng - 2191,  
 South Africa.  
 T +27 11 465-2049  
 F +27 86 471 7941

Meril Medical LLC.  
 Nauchnyi Proezd 19,  
 Moscow, Russia - 117 246.  
 Office - +7 495 772 7643

EU representative.  
 Obelis S.A.  
 Bd. General Wahis 53,  
 1030, Brussels, Belgium.  
 T +32 2 732 5954  
 F +32 2 732 6003  
 E mail@obelis.net

CE 1783

E askinfo@merillife.com  
 W www.merillife.com

MeRes100™

Sirolimus Eluting BioResorbable Vascular Scaffold System

Meril

ri More to Life

CE

MRL25013/001/MRL27519/001/190




# MeRes100<sup>TM</sup>

Sirolimus Eluting BioResorbable Vascular Scaffold System

Simply *Sublime*.

## Next Generation BioResorbable Scaffold.



Size Matrix  
 Diameters - 2.50, 2.75, 3.00, 3.25, 3.50, 4.00, 4.50 mm  
 Lengths - 13, 16, 19, 24, 29, 32, 37, 40 mm



## MeRes-1 first-in-man safety and efficacy study in patients with single, de-novo coronary lesion (in up to two vessels) treated by MeRes100 - BRS.




N = 108, Prospective, Non-Randomized, Multi-Centre Study (16 Investigating sites in India)

**Primary Demographics-Treatment Influencing Factors**  
 Diabetics (28%), Hypertensive (42%), Dyslipidemics (13%), Smokers (17%)

**Lesion characteristics-Lesion class A (7%), B1 (32%), B2 (56%), C (5%)**

**Post Dilatation 108 (100%) and Device Success 108 (100%)**


Clinical Endpoint	In-Hospital N = 108 (100%)	1-Month N = 108 (100%)	6-Months N = 108 (100%)	1-Year N = 107 (99%)
<b>MACE Composite of</b>	<b>0 (0%)</b>	<b>0 (0%)</b>	<b>0 (0%)</b>	<b>1 (0.93%)</b>
Cardiac Death	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Myocardial Infarction <sup>o</sup>	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Ischemia-driven TLR	0 (0%)	0 (0%)	0 (0%)	1 (0.93%)
Ischemia-driven TVR	0 (0%)	0 (0%)	0 (0%)	0 (0%)
<b>Scaffold Thrombosis<sup>s</sup></b>	<b>0 (0%)</b>	<b>0 (0%)</b>	<b>0 (0%)</b>	<b>0 (0%)</b>
<b>Non-cardiac death</b>	<b>0 (0%)</b>	<b>0 (0%)</b>	<b>1<sup>*</sup> (0.9%)</b>	<b>0 (0%)</b>



## MeRes100 - BRS Implantation<sup>2</sup>

### Proximal LAD sub-occlusive stenosis and clinical outcome.

53 Years | Male | Diabetic | Hypertensive | No family history | Non-smoker | Stable angina



<sup>o</sup>Seth A. et al. EuroIntervention 2017;13:415-423.  
<sup>s</sup> Myocardial Infarction defined as per WHO criteria. <sup>\*</sup> Death due to aminophylline induced anaphylactic shock. <sup>2</sup> SRC defined criteria.